top of page
Search

Vancouver-based BIOVAXYS completes first tranche of financing, raising $1,103,500

BioVaxys Technology is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix 'neoantigen' tumor cell construct platform for treating refractive late-stage ovarian cancer and other tumor types. 


BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)  ("BioVaxys" or the "Company") announces that it has completed the first tranche of a non-brokered private placement (the "Private Placement") consisting of 36,783,334 ("Units") at a price of $0.03 per Unit for total gross proceeds of $1,103,500. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.05 for a period of 48 months.


All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company intends to use the net proceeds of the Private Placement for working capital purposes. The private placement is subject to the approval of the Canadian Securities Exchange.


The Company will pay a finder's fee of $57,400 in cash related to the financing.


The Company anticipates closing the second and final tranche of the private placement no later than February 9th, 2024.


About BioVaxys Technology Corp.


BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company based in Vancouver, Canada, is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late-stage ovarian cancer and other tumor types.   The Company is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.  BioVaxys is also pursuing vaccines based on its HapTenix© platform for various emerging viral infections. 


BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).


Source: BioVaxys Technology Corp.


#biovaxys @medicalandpharmainsider #cancer

________________________________________________________________

What are your company's business or financial objectives?









If your company has business or financial objectives, check out the advisory services for growing life sciences companies provided by FC Global Strategies.


Our calendar link to schedule a complementary call.


FC Global Strategies' Regional Directors:


Jeffrey Friedland - Based in the U.S.

(North America and Global)

+1 646 450 8909


Ross Swan - Based in Singapore

(Southeast Asia, Australia, Asia-Pacific)

+65 9181 9472


David Krutonog - Based in Israel

(Eastern Europe, Middle-East and North Africa

+972 50 974 3429


Claudio Hebling - Based in Brazil

(Latin America)

+55 19 99377 748


Vincent Paul Joseph - Based in India

(South Asia, India and Sri Lanka)

+91 962 620 9090


Olah Abiodun - Based in Nigeria

(Sub-Saharan Africa)

+234 812 029 8222







Comments


Commenting has been turned off.
bottom of page